NASDAQ:AMRS Amyris Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Amyris Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.82 -0.06 (-2.08 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$2.80Now: $2.83▼$3.1050-Day Range$2.33MA: $3.44▼$4.9452-Week Range$1.40Now: $2.83▼$6.07Volume8.76 million shsAverage Volume2.50 million shsMarket Capitalization$578.37 millionP/E RatioN/ADividend YieldN/ABeta0.45 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Amyris, Inc., an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products. The company delivers its No Compromise products and services in markets, such as specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAmyris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Amyris has a forecasted upside of 254.0% from its current price of $2.83.Amount of Analyst CoverageAmyris has only been the subject of 1 research reports in the past 90 days. Previous Next 1.9 Community Rank Outperform VotesAmyris has received 316 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAmyris has received 507 “underperform” votes. (Add your “underperform” vote.)Community SentimentAmyris has received 61.60% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Amyris and other stocks. Vote “Outperform” if you believe AMRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AMRS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAmyris does not currently pay a dividend.Dividend GrowthAmyris does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amyris insiders have not sold or bought any company stock.Percentage Held by Insiders39.70% of the stock of Amyris is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions37.80% of the stock of Amyris is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amyris are expected to grow in the coming year, from ($1.23) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amyris is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amyris is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.61 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Industrial organic chemicals Sub-IndustryOil & Gas Refining & Marketing SectorBasic Materials Current SymbolNASDAQ:AMRS Previous Symbol CUSIP03236M10 CIK1365916 Webamyris.com Phone510-450-0761Debt Debt-to-Equity RatioN/A Current Ratio1.48 Quick Ratio1.22Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$152.56 million Price / Sales3.79 Cash FlowN/A Price / Cash FlowN/A Book Value($2.17) per share Price / Book-1.30Profitability EPS (Most Recent Fiscal Year)($2.72) Net Income$-242,770,000.00 Net Margins-245.73% Return on EquityN/A Return on Assets-182.75%Miscellaneous Employees414 Outstanding Shares204,731,000Market Cap$578.37 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $2.82 -0.06 (-2.08 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AMRS News and Ratings via Email Sign-up to receive the latest news and ratings for AMRS and its competitors with MarketBeat's FREE daily newsletter. Amyris (NASDAQ:AMRS) Frequently Asked Questions How has Amyris' stock price been impacted by COVID-19? Amyris' stock was trading at $2.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AMRS stock has decreased by 4.6% and is now trading at $2.8250. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Amyris? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amyris. When is Amyris' next earnings date? Amyris is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Amyris. How were Amyris' earnings last quarter? Amyris Inc (NASDAQ:AMRS) issued its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.56) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.37. The biotechnology company had revenue of $30.01 million for the quarter, compared to analyst estimates of $35.76 million. View Amyris' earnings history. When did Amyris' stock split? How did Amyris' stock split work? Amyris shares reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split. What guidance has Amyris issued on next quarter's earnings? Amyris updated its FY 2020 Pre-Market earnings guidance on Thursday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $220.32-220.32 million, compared to the consensus revenue estimate of $220.6 million. What price target have analysts set for AMRS? 2 brokerages have issued twelve-month price objectives for Amyris' stock. Their forecasts range from $9.00 to $11.00. On average, they expect Amyris' share price to reach $10.00 in the next year. This suggests a possible upside of 254.0% from the stock's current price. View analysts' price targets for Amyris. Who are some of Amyris' key competitors? Some companies that are related to Amyris include Phillips 66 (PSX), Marathon Petroleum (MPC), Valero Energy (VLO), HollyFrontier (HFC), Renewable Energy Group (REGI), World Fuel Services (INT), CVR Energy (CVI), Delek US (DK), PBF Energy (PBF), Clean Energy Fuels (CLNE), Green Plains (GPRE), REX American Resources (REX), Adams Resources & Energy (AE) and Gevo (GEVO). View all competitors. What other stocks do shareholders of Amyris own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Nokia Oyj (NOK), Sorrento Therapeutics (SRNE), Gevo (GEVO), Novavax (NVAX), AT&T (T), NVIDIA (NVDA), Pfizer (PFE) and General Electric (GE). Who are Amyris' key executives? Amyris' management team includes the following people: Mr. John G. Melo, Pres, CEO & Director (Age 53)Ms. Kathleen Valiasek, Chief Financial Officer (Age 55)Mr. Eduardo Alvarez, Chief Operating Officer (Age 55)Ms. Nicole Kelsey, Gen. Counsel & Sec. (Age 52)Dr. Joel R. Cherry, Pres of R&D (Age 58) What is Amyris' stock symbol? Amyris trades on the NASDAQ under the ticker symbol "AMRS." Who are Amyris' major shareholders? Amyris' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (8.74%), RTW Investments LP (1.90%), Hudson Bay Capital Management LP (1.55%), Perceptive Advisors LLC (0.90%), Pinnacle Associates Ltd. (1.03%) and Nantahala Capital Management LLC (1.02%). Company insiders that own Amyris stock include Eduardo Alvarez, Frank Kung, John Melo, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View institutional ownership trends for Amyris. Which major investors are selling Amyris stock? AMRS stock was sold by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Pinnacle Associates Ltd., Essex Investment Management Co. LLC, UBS Group AG, Spark Investment Management LLC, Virtus ETF Advisers LLC, Baird Financial Group Inc., and Envestnet Asset Management Inc.. Company insiders that have sold Amyris company stock in the last year include John Melo, and Patrick Y Yang. View insider buying and selling activity for Amyris. Which major investors are buying Amyris stock? AMRS stock was bought by a variety of institutional investors in the last quarter, including RTW Investments LP, Perceptive Advisors LLC, Nantahala Capital Management LLC, FMR LLC, Monashee Investment Management LLC, Virtu Financial LLC, Bank of America Corp DE, and Algert Global LLC. Company insiders that have bought Amyris stock in the last two years include Eduardo Alvarez, Frank Kung, Kathleen Valiasek, and L John Doerr. View insider buying and selling activity for Amyris. How do I buy shares of Amyris? Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Amyris' stock price today? One share of AMRS stock can currently be purchased for approximately $2.83. How big of a company is Amyris? Amyris has a market capitalization of $578.37 million and generates $152.56 million in revenue each year. The biotechnology company earns $-242,770,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Amyris employs 414 workers across the globe. What is Amyris' official website? The official website for Amyris is amyris.com. How can I contact Amyris? Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
